GlassScriptPhysician profile
Mark Donald Hall
NPI 1578833026
$3,081.97
in general payments reported to CMS, 2019-2025
29 companies · $564 in 2025
The $564 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $780 · 2022: $761 · 2023: $551 · 2024: $427 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,541.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $679.75 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $423.41 | 2021-2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $384.16 | 2021-2025 | Relistor |
| Averitas Pharma INC. | $326.88 | 2023-2025 | Qutenza |
| Grt US Holding, INC. | $266.52 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $147.65 | 2021-2022 | |
| Boston Scientific Corporation | $144.35 | 2022-2025 | Intracept, Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $137.72 | 2021-2024 | Intellis Adaptivestim |
| Novartis Pharmaceuticals Corporation | $64.84 | 2021 | |
| Ferring Pharmaceuticals INC. | $55.50 | 2022-2025 | Euflexxa |
| Allergan, INC. | $54.30 | 2021 | |
| Azurity Pharmaceuticals, INC. | $32.72 | 2023 | Horizant |
| Redhill Biopharma INC. | $32.42 | 2021-2022 | |
| Bioventus LLC | $31.18 | 2022-2025 | Durolane |
| Valinor Pharma, LLC | $29.24 | 2025 | Movantik |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $29.09 | 2021 | |
| Merz Pharmaceuticals, LLC | $28.72 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $27.91 | 2025 | |
| Globus Medical, INC. | $25.56 | 2025 | Senza |
| Braeburn INC. | $23.55 | 2024 | Brixadi |
| Pacira Pharmaceuticals Incorporated | $21.32 | 2024 | Zilretta, Iovera |
| Forte Bio-Pharma LLC | $18.75 | 2023 | Prolate, Nalocet |
| Bard Peripheral Vascular, INC. | $17.94 | 2024 | Venclose Maven Catheter |
| Pfizer INC. | $15.01 | 2023 | |
| Nevro Corp. | $13.76 | 2023 | Senza |
| Ibsa Pharma INC. | $13.28 | 2021 | |
| Almatica Pharma LLC | $12.70 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.88 | 2021 | |
| Amgen INC. | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.